Project Grant R00HG012576
- This Project Grant awarded by the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $844,954 to New York University School of Medicine to develop "Genomically Rewritten and Tailored Humanized Mouse Models for Various Organ Disorders." The project leverages advanced DNA synthesis and editing capabilities to create genetically engineered mouse models (GREAT-GEMMs) that accurately represent specific human disease phenotypes. These...
- This $2,624,970 federal Project Grant, awarded by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), aims to construct the first-ever foundational in silico (computational) model of whole-embryo mouse embryogenesis. The project will leverage cutting-edge sequencing technology and machine learning techniques to establish a large-scale 3D multi-omics cell atlas of mouse embryogenesis from embryonic day 6.5 to 16.5, involving a total of 50 million...
- This federal Project Grant award for $378,123 from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to identify and test mechanisms that establish transcriptional regulatory potency in early embryos. The primary activities include using genomic methods like PRO-seq, DREG, and OMNI-ATAC to characterize transcriptionally active regulatory elements, DNA accessibility, and...
- The Whitehead Institute for Biomedical Research was awarded a $125,000 Project Grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The purpose of this 2-year grant is to develop and leverage the PETRACER technology platform to create integrated maps of cell state and lineage during normal mouse embryonic development. The research aims to delineate how...
- This federal Project Grant award of $128,898 was provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant supports research to elucidate how the 3D genome regulates the transcriptional program during mouse spermatogenesis, with the goal of providing insight into how male germ cell identity is established. The principal investigator will perform high-resolution Hi-C analysis...
- This Project Grant award of $261,017.00 was provided by the National Institutes of Health (NIH) Office of the Director through the Research Infrastructure Programs (CFDA 93.351) to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. The grant supports the development of a mouse model system for targeted trimming of disease susceptibility loci, which aims to streamline the identification of genes responsible for particular traits or diseases. The proposed approach...
- This Project Grant award from the National Institutes of Health (NIH) Office of Research Infrastructure Programs (CFDA 93.351) provides $775,888 to the La Jolla Institute for Immunology to develop a next-generation CRISPR-ready, HLA class I and II transgenic mouse platform. The goal is to create a modular, CAS9-expressing mouse strain from which investigators can generate HLA class I or II transgenic mice for a broad range of disease research, including infection, cancer, autoimmunity, and...
- This federal Project Grant award of $135,206 from the National Human Genome Research Institute (NHGRI), under the Human Genome Research Federal Grant Program (CFDA 93.172), supports the development of two novel single-cell functional genomic technologies to investigate the causal relationship between DNA methylation changes and gene expression in human diseases. The award recipient, The Regents of the University of California, San Francisco (UCSF), aims to: 1) Develop a single-cell version of...
- This federal Project Grant award of $1,350,896, awarded on January 1, 2025 by the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), supports the development of a multimodal massively parallel reporter assay (MPRA) platform to study regulatory sequence function. The overarching goal is to create tools that can elucidate the mechanisms and grammar by which regulatory elements in the genome encode interactions between chromatin, regulatory...
- This Project Grant award of $3,498,931.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to comprehensively investigate the impact of loss of 100 neurodevelopmental and psychiatric disorder (NPD) genes in mice. The project, titled "Cross Scale Interrogation of NPD Genes (SING) in Mice", will utilize knockout mouse models to examine gene expression, cellular changes, neural circuits, and behaviors across multiple...
DEVELOPMENT OF FUNCTIONAL GENOMIC TECHNOLOGIES IN MICE - PROJECT SUMMARY MUTATIONS IN GENE REGULATORY ELEMENTS (RES) ARE A MAJOR CAUSE OF HUMAN DISEASE. FOR EXAMPLE, THE MAJORITY (>90%) OF DISEASE RELATED GENOME WIDE ASSOCIATION STUDIES (GWAS) FOUND ASSOCIATIONS WITH VARIANTS IN NON- CODING AND LIKELY REGULATORY REGIONS IN THE GENOME. DESPITE THEIR IMPORTANCE, THE CODE AND GRAMMAR OF THESE REGULATORY ELEMENTS REMAINS LARGELY UNKNOWN MAKING THE UNDERSTANDING OF HOW MUTATIONS IN THESE SEQUENCES CAN LEAD TO DISEASE EVEN MORE COMPLEX. REGULATORY ELEMENTS CAN BE IDENTIFIED IN A GENOME-WIDE MANNER USING TECHNIQUES SUCH AS CHIP-SEQ OR ATAC-SEQ. HOWEVER, THESE METHODS ARE DESCRIPTIVE AND DO NOT PROVIDE A FUNCTIONAL READOUT THAT TESTS WHETHER THESE ELEMENTS ARE INDEED FUNCTIONAL. MASSIVELY PARALLEL REPORTER ASSAYS (MPRAS) AND CRISPR-BASED SCREENS HAVE RECENTLY BEEN DEVELOPED TO FUNCTIONALLY CHARACTERIZED THESE ELEMENTS IN A HIGH-THROUGHPUT MANNER. HOWEVER, MOST OF THESE TECHNIQUES USE CULTURED CELLS TO MEASURE ACTIVITY. AS SUCH, THE ACTIVITY AND FUNCTION OF THESE ELEMENTS AND THEIR VARIANTS IN AN ORGANISM HAS NOT BEEN TESTED. DUE TO THIS, COMPLEX PHENOTYPES, SUCH AS SPATIAL-TEMPORAL, AND TISSUE/CELL TYPE SPECIFICITY AND INTERACTIONS CANNOT BE ASSESSED FOR THESE ELEMENTS. IN THIS K99/R00 APPLICATION, I WILL DEVELOP TECHNOLOGIES THAT WILL ALLOW TO FUNCTIONALLY CHARACTERIZE REGULATORY ELEMENTS AND VARIANTS IN A HIGH THROUGHPUT MANNER IN MICE. ONE OF THE BIGGEST BARRIERS THAT PREVENT HIGH-THROUGHPUT ASSAYS IN MICE IS THE ZONA PELLUCIDA THAT SURROUNDS ONE-CELL STAGE EMBRYOS AND PREVENTS DOUBLE-STRANDED DNA TO BE INSERTED. RECENT REPORTS AND MY OWN PRELIMINARY DATA SHOW THAT BY UTILIZING ADENO ASSOCIATED VIRUS SEROTYPE 6 (AAV6) AS A DELIVERY TOOL, DNA CAN INTEGRATE INTO ONE-CELL STAGE EMBRYOS. I PLAN TO USE AAV6 ALONG WITH THE PIGGYBAC TRANSPOSASE SYSTEM, THAT ALLOWS FOR GENOMIC INTEGRATION IN ALL THREE-GERM LAYERS, TO DEVELOP MPRA IN MICE (AIM K1). TO VALIDATE THE EFFECT OF SINGLE NUCLEOTIDE VARIANTS, I WILL DEVELOP LARGE-SCALE CRISPR SATURATION MUTAGENESIS ASSAYS IN MICE. THIS WILL BE DONE BY UTILIZING IN VITRO ELECTROPORATION INTO EMBRYOS AND BASE-EDITOR OR PRIME-EDITOR TRANSGENIC MICE (AIM K2). FINALLY, I WILL APPLY THESE TECHNOLOGIES TO GENERATE A CATALOG OF FUNCTIONAL REGULATORY ELEMENTS, INCLUDING TRANSPOSABLE ELEMENTS, INVOLVED IN DIFFERENTIATION OF THE THREE PRIMARY GERM LAYERS (AIM R1). THE RESULTS FROM THIS PROPOSAL WILL PROVIDE NOVEL IN VIVO HIGH-THROUGHPUT TECHNOLOGIES THAT WILL ENABLE TO STUDY REGULATORY ELEMENTS AND DISEASE-ASSOCIATED VARIANTS AT ANY DEVELOPMENTAL TIME STAGE IN MICE. MY CAREER GOAL IS TO LEAD AN INDEPENDENT RESEARCH GROUP DEVELOPING NOVEL FUNCTIONAL GENOMICS TOOLS IN MICE AND STUDYING THE FUNCTION OF GENE REGULATORY ELEMENTS AND THEIR VARIANTS IN TISSUE DEVELOPMENT AND DISEASE UTILIZING THESE TECHNOLOGIES. TO ACHIEVE THIS GOAL, I WILL RECEIVE EXPERIMENTAL AND COMPUTATIONAL TRAINING FROM MY MENTORS DRS. NADAV AHITUV AND JAY SHENDURE. THIS RIGOROUS MENTORED SUPPORT AND RESULTS OBTAINED IN THE K99 PHASE WILL ENSURE MY TRANSITION TO AN INDEPENDENT INVESTIGATOR AND FUTURE SUCCESSFUL INDEPENDENT CAREER.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $224.1k | 4/17/25 |